Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Laroni

Showing results (31-40 of 75) with videos related to

Pageof 8
Sort By:
Frontiers in Immunology|March 29, 2021
Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two GroupsGloria Donninelli, Valeria Studer, Laura Brambilla, et al.
Human Vaccines & Immunotherapeutics|July 21, 2022
Vaccinations in patients with multiple sclerosis: a real-world, single-center experienceElvira Sbragia, Dario Olobardi, Giovanni Novi, et al.
Nature Immunology|August 3, 2010
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cellsRoopali Gandhi, Deepak Kumar, Evan J Burns, et al.
Immunology Letters|December 7, 2016
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanomaIlaria Gandoglia, Federico Ivaldi, Paolo Carrega, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 11, 2017
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MSGiulia Bommarito, Alessandro Bellini, Matteo Pardini, et al.
Multiple Sclerosis and Related Disorders|January 25, 2022
High or increasing serum NfL is predictive of impending multiple sclerosis relapsesSimon Thebault, Michael Reaume, Ruth Ann Marrie, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 24, 2019
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter studyPasquale Annunziata, Gianni Masi, Chiara Cioni, et al.
Multiple Sclerosis and Related Disorders|January 5, 2023
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosisIrene Schiavetti, Lucrezia Barcellini, Caterina Lapucci, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 21, 2016
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in ItalyAlice Laroni, Davide Brogi, Vincenzo Brescia Morra, et al.
BMC Neurology|April 3, 2014
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trialAlice Laroni, Davide Brogi, Vincenzo Brescia Morra, et al.
Pageof 8

Showing results (31-40 of 75) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|March 29, 2021
Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two GroupsGloria Donninelli, Valeria Studer, Laura Brambilla, et al.
Human Vaccines & Immunotherapeutics|July 21, 2022
Vaccinations in patients with multiple sclerosis: a real-world, single-center experienceElvira Sbragia, Dario Olobardi, Giovanni Novi, et al.
Nature Immunology|August 3, 2010
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cellsRoopali Gandhi, Deepak Kumar, Evan J Burns, et al.
Immunology Letters|December 7, 2016
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanomaIlaria Gandoglia, Federico Ivaldi, Paolo Carrega, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 11, 2017
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MSGiulia Bommarito, Alessandro Bellini, Matteo Pardini, et al.
Multiple Sclerosis and Related Disorders|January 25, 2022
High or increasing serum NfL is predictive of impending multiple sclerosis relapsesSimon Thebault, Michael Reaume, Ruth Ann Marrie, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 24, 2019
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter studyPasquale Annunziata, Gianni Masi, Chiara Cioni, et al.
Multiple Sclerosis and Related Disorders|January 5, 2023
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosisIrene Schiavetti, Lucrezia Barcellini, Caterina Lapucci, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 21, 2016
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in ItalyAlice Laroni, Davide Brogi, Vincenzo Brescia Morra, et al.
BMC Neurology|April 3, 2014
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trialAlice Laroni, Davide Brogi, Vincenzo Brescia Morra, et al.
Pageof 8